Anti-proliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines.

@article{Gandhi2004AntiproliferativeAO,
  title={Anti-proliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines.},
  author={Anita K. Gandhi and Syedah D Naziruddin and Dominique Verhelle and Helen Brady and Peter H. Schafer and David I. Stirling},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={6618}
}
6618 Background: Phase I/II studies of CC-5013 (Revimid™) in MDS have shown erythropoietic and cytogenetic responses, especially among 5q- patients. The 5q deletion is a primary chromosomal change among various hematological malignancies including MDS, and it affects expression of genes on the locus including the tumor suppressor interferon regulatory… CONTINUE READING